Dopaminergic and cholinergic lesions in progressive supranuclear palsy. 1985

M Ruberg, and F Javoy-Agid, and E Hirsch, and B Scatton, and R LHeureux, and J J Hauw, and C Duyckaerts, and F Gray, and A Morel-Maroger, and A Rascol

In 9 patients with progressive supranuclear palsy and in 27 controls, dopamine and homovanillic acid concentrations, choline acetyltransferase (CAT) activity, and the number of [3H]spiperone and [3H]quinuclidinyl benzilate binding sites were measured post mortem in the striatum (caudate nucleus, putamen, and nucleus accumbens), substantia innominata, and frontal cortex. Dopamine and homovanillic acid concentrations were reduced in the caudate nucleus and putamen but not in the nucleus accumbens or frontal cortex, indicating that the nigrostriatal dopaminergic system is lesioned in patients with progressive supranuclear palsy (as in those with Parkinson's disease) but not the mesocortical and mesolimbic dopaminergic systems, which are lesioned in parkinsonian patients. CAT activity and [3H]spiperone binding decreased in parallel fashion in all the structures. In the striatum, this suggests that the cholinergic neurons, which are target cells of the nigrostriatal system, also degenerate in this disease. This might explain the decrease in the number of dopamine receptors as well as the inefficacy of levodopa or anticholinergic therapy in these patients. The decrease in CAT activity in the substantia innominata and the frontal cortex indicates that the innominatocortical cholinergic system is lesioned in patients with progressive supranuclear palsy and may play a role in the intellectual deterioration observed. This lesion is also found in demented patients with Alzheimer's and Parkinson's diseases.

UI MeSH Term Description Entries
D008297 Male Males
D009410 Nerve Degeneration Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways. Neuron Degeneration,Degeneration, Nerve,Degeneration, Neuron,Degenerations, Nerve,Degenerations, Neuron,Nerve Degenerations,Neuron Degenerations
D009435 Synaptic Transmission The communication from a NEURON to a target (neuron, muscle, or secretory cell) across a SYNAPSE. In chemical synaptic transmission, the presynaptic neuron releases a NEUROTRANSMITTER that diffuses across the synaptic cleft and binds to specific synaptic receptors, activating them. The activated receptors modulate specific ion channels and/or second-messenger systems in the postsynaptic cell. In electrical synaptic transmission, electrical signals are communicated as an ionic current flow across ELECTRICAL SYNAPSES. Neural Transmission,Neurotransmission,Transmission, Neural,Transmission, Synaptic
D010244 Bulbar Palsy, Progressive A motor neuron disease marked by progressive weakness of the muscles innervated by cranial nerves of the lower brain stem. Clinical manifestations include dysarthria, dysphagia, facial weakness, tongue weakness, and fasciculations of the tongue and facial muscles. The adult form of the disease is marked initially by bulbar weakness which progresses to involve motor neurons throughout the neuroaxis. Eventually this condition may become indistinguishable from AMYOTROPHIC LATERAL SCLEROSIS. Fazio-Londe syndrome is an inherited form of this illness which occurs in children and young adults. (Adams et al., Principles of Neurology, 6th ed, p1091; Brain 1992 Dec;115(Pt 6):1889-1900) Fazio-Londe Disease,Fazio-Londe Syndrome,Fazio-Londe's Disease,Fazio-Londe's Syndrome,Paralysis, Bulbar,Bulbar Palsy,Bulbar Palsy, Progressive, Of Childhood,Childhood Progressive Bulbar Palsy,Progressive Bulbar Palsy of Childhood,Bulbar Palsies,Bulbar Palsies, Progressive,Bulbar Paralyses,Bulbar Paralysis,Disease, Fazio-Londe,Disease, Fazio-Londe's,Fazio Londe Disease,Fazio Londe Syndrome,Fazio Londe's Disease,Fazio Londe's Syndrome,Palsies, Bulbar,Palsies, Progressive Bulbar,Palsy, Bulbar,Palsy, Progressive Bulbar,Progressive Bulbar Palsies,Syndrome, Fazio-Londe,Syndrome, Fazio-Londe's
D010302 Parkinson Disease, Secondary Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42) Atherosclerotic Parkinsonism,Secondary Parkinsonism,Symptomatic Parkinson Disease,Parkinson Disease, Secondary Vascular,Parkinson Disease, Symptomatic,Parkinsonism, Secondary,Parkinsonism, Symptomatic,Secondary Vascular Parkinson Disease,Parkinsonism, Atherosclerotic,Secondary Parkinson Disease,Symptomatic Parkinsonism
D011813 Quinuclidinyl Benzilate A high-affinity muscarinic antagonist commonly used as a tool in animal and tissue studies. Benzilate, Quinuclidinyl
D011950 Receptors, Cholinergic Cell surface proteins that bind acetylcholine with high affinity and trigger intracellular changes influencing the behavior of cells. Cholinergic receptors are divided into two major classes, muscarinic and nicotinic, based originally on their affinity for nicotine and muscarine. Each group is further subdivided based on pharmacology, location, mode of action, and/or molecular biology. ACh Receptor,Acetylcholine Receptor,Acetylcholine Receptors,Cholinergic Receptor,Cholinergic Receptors,Cholinoceptive Sites,Cholinoceptor,Cholinoceptors,Receptors, Acetylcholine,ACh Receptors,Receptors, ACh,Receptor, ACh,Receptor, Acetylcholine,Receptor, Cholinergic,Sites, Cholinoceptive
D011954 Receptors, Dopamine Cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behavior of cells. Dopamine Receptors,Dopamine Receptor,Receptor, Dopamine
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002795 Choline O-Acetyltransferase An enzyme that catalyzes the formation of acetylcholine from acetyl-CoA and choline. EC 2.3.1.6. Choline Acetylase,Choline Acetyltransferase,Acetylase, Choline,Acetyltransferase, Choline,Choline O Acetyltransferase,O-Acetyltransferase, Choline

Related Publications

M Ruberg, and F Javoy-Agid, and E Hirsch, and B Scatton, and R LHeureux, and J J Hauw, and C Duyckaerts, and F Gray, and A Morel-Maroger, and A Rascol
August 2007, Movement disorders : official journal of the Movement Disorder Society,
M Ruberg, and F Javoy-Agid, and E Hirsch, and B Scatton, and R LHeureux, and J J Hauw, and C Duyckaerts, and F Gray, and A Morel-Maroger, and A Rascol
February 2005, Brain : a journal of neurology,
M Ruberg, and F Javoy-Agid, and E Hirsch, and B Scatton, and R LHeureux, and J J Hauw, and C Duyckaerts, and F Gray, and A Morel-Maroger, and A Rascol
January 1991, Neurology,
M Ruberg, and F Javoy-Agid, and E Hirsch, and B Scatton, and R LHeureux, and J J Hauw, and C Duyckaerts, and F Gray, and A Morel-Maroger, and A Rascol
April 2002, Neurology,
M Ruberg, and F Javoy-Agid, and E Hirsch, and B Scatton, and R LHeureux, and J J Hauw, and C Duyckaerts, and F Gray, and A Morel-Maroger, and A Rascol
January 2022, Frontiers in aging neuroscience,
M Ruberg, and F Javoy-Agid, and E Hirsch, and B Scatton, and R LHeureux, and J J Hauw, and C Duyckaerts, and F Gray, and A Morel-Maroger, and A Rascol
January 1992, Clinical neuropathology,
M Ruberg, and F Javoy-Agid, and E Hirsch, and B Scatton, and R LHeureux, and J J Hauw, and C Duyckaerts, and F Gray, and A Morel-Maroger, and A Rascol
January 1994, Journal of neural transmission. Supplementum,
M Ruberg, and F Javoy-Agid, and E Hirsch, and B Scatton, and R LHeureux, and J J Hauw, and C Duyckaerts, and F Gray, and A Morel-Maroger, and A Rascol
July 1994, Annals of neurology,
M Ruberg, and F Javoy-Agid, and E Hirsch, and B Scatton, and R LHeureux, and J J Hauw, and C Duyckaerts, and F Gray, and A Morel-Maroger, and A Rascol
July 2010, Brain : a journal of neurology,
M Ruberg, and F Javoy-Agid, and E Hirsch, and B Scatton, and R LHeureux, and J J Hauw, and C Duyckaerts, and F Gray, and A Morel-Maroger, and A Rascol
September 1982, Archives of neurology,
Copied contents to your clipboard!